Uveitis Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The uveitis treatment market size was valued at USD 2.56 billion in 2025 and estimated to grow from USD 2.73 billion in 2026 to reach USD 3.78 billion by 2031, at a CAGR of 6.72% during the forecast period (2026-2031). This report is Segmented by Drug Class (Corticosteroids, Immunosuppressants, Biologics / Biosimilars, and More), Disease Type (Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, and Panuveitis), Route of Administration (Topical, and More), Distribution Channel (Hospital Pharmacies, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Uveitis Treatment Market Trends and Insights

Rising Incidence Of Uveitis & Vision-Threatening Complications

The cumulative incidence of uveitis reached 60 per 100,000 and prevalence hit 285 per 100,000 in the United States by 2023, yet anterior cases remain under-diagnosed in primary care. Systemic autoimmune disease comorbidities such as ankylosing spondylitis amplify detection rates as rheumatology referrals rise. Posterior and intermediate forms now represent about 55% of presentations and require costlier biologics or implants to avert irreversible vision loss, thereby boosting per-patient spend. Epidemiologic shifts toward more severe phenotypes elevate therapy duration and complexity, expanding the uveitis treatment market beyond headline patient numbers. Premium implant platforms that deliver drugs for months from a single procedure gain traction as clinicians seek durable inflammation control with fewer systemic risks.

Growing R&D Spend On Novel Biologics & Implants

Merck’s USD 1.3 billion purchase of EyeBio for its tetravalent antibody program underscored industry appetite for multi-target biologics that address both inflammation and retinal repair. FDA approval of Roche’s Susvimo, offering nine-month refill intervals, validated sustained-release implants as commercially viable. Non-viral gene therapy start-ups attracted fresh venture capital, signalling a pivot toward potentially curative approaches that could lower lifetime treatment costs while reshaping competitive dynamics. These developments collectively expand therapeutic choice, compress injection frequency, and raise barriers to entry for conventional corticosteroids.

High Cost & Systemic Side-Effects Of Current Therapies

Annual systemic adalimumab therapy can surpass USD 60,000 per patient, whereas long-acting implants such as YUTIQ demand high upfront outlays despite three-year durability. TNF-alpha inhibitors also impose infection monitoring costs that inflate total expenditure by up to 30%. Business-driven trial discontinuations, exemplified by the HUMBOLDT study ending despite favourable filgotinib data, highlight how commercial viability shapes the therapy landscape. High costs therefore restrict uptake, particularly in markets with low per-capita healthcare spend.

Other drivers and restraints analyzed in the detailed report include:

• Expanding Access To Ophthalmic Care In Emerging Economies
• Increasing Adoption Of Biosimilar Adalimumab & Infliximab
• Limited Ophthalmology Specialist Workforce In Low-Income Regions

Segment Analysis

Corticosteroids retained 40.89% revenue share in 2025, yet biologics and biosimilars expanded at a 9.11% CAGR, reflecting clinician migration toward targeted agents that avoid cataract formation and intraocular pressure spikes. The recent six-month shortage of triamcinolone acetonide highlighted supply chain fragility and encouraged pivoting to sustained-release implants. The uveitis treatment market size for biologics is projected to advance faster than any other drug class through 2031 as pipeline JAK inhibitors progress into Phase 3. Immunosuppressants remain vital bridge therapies, and anti-infectives support the smaller infectious subset, maintaining a balanced but shifting drug-class landscape.

Second-generation biologics diversify mechanisms to include bispecific antibodies and Wnt pathway modulators, intensifying competition yet widening choice. Biosimilar launches create tiered price points that broaden patient access while preserving manufacturer margins through volume. The uveitis treatment industry therefore faces accelerating product proliferation alongside consolidation of legacy corticosteroid lines.

Anterior uveitis led revenue with 43.76% share in 2025 because of high incidence and topical therapy reliance, but posterior uveitis is forecast to be the fastest-growing category at an 8.72% CAGR on account of specialised delivery needs such as suprachoroidal injections. The uveitis treatment market share for posterior forms is poised to expand as clinicians adopt implants that reduce retreatment frequency. New data showing faricimab efficacy in uveitic macular edema open further premium therapy avenues. Intermediate uveitis shows steady but moderate growth, while panuveitis remains the highest acuity segment with persistent unmet needs.

Adoption of diagnostic imaging advances, including wide-field OCT and AI algorithms, improves posterior disease detection and supports earlier intervention. This contributes to sustained revenue gains even as payer scrutiny rises. Consequently, the uveitis treatment market continues to shift toward segments involving complex pathophysiology and expensive interventions.

Complete Report Scope:

• By Drug Class
  • Corticosteroids
  • Immunosuppressants
  • Biologics / Biosimilars
  • Antimicrobials (Antibiotics, Antivirals, Antifungals)
  • NSAIDs & Analgesics
  • Others
• By Disease Type
  • Anterior Uveitis
  • Posterior Uveitis
  • Intermediate Uveitis
  • Panuveitis
• By Route of Administration
  • Topical (Eye Drops & Ointments)
  • Oral / Systemic
  • Local Ocular Injections (Intravitreal, Suprachoroidal, Periocular)
  • Ocular Implants & Inserts
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated 38.11% of global revenue in 2025, underpinned by widespread insurance coverage, early biologic uptake, and a robust clinical trial ecosystem. The region’s CAGR is expected to moderate as the market matures, although shortages of prednisolone acetate and difluprednate highlight supply-chain vulnerabilities that could redirect prescriptions toward alternative formulations. Workforce adequacy remains a looming challenge, with a projected 30% deficit by 2035 that may cap procedure volumes despite strong therapy demand.

Asia-Pacific posts the fastest-growing trajectory at an 8.74% CAGR as large patient backlogs meet rising healthcare expenditure. China’s Phase 3 success with ARCATUS, showing a 38.5% rate of 15+ ETDRS letter gains, exemplifies regional progress toward premium therapy adoption. Japan continues to pioneer extended-interval anti-VEGF regimens, and Australia often serves as a regulatory gateway for multinational launches. Nevertheless, ophthalmologist density remains uneven, with certain countries reporting zero specialists per million population compared with Japan’s 114 per million.

Europe maintains balanced growth as biosimilar-friendly policies sustain biologic uptake. EMA procedures offer predictable timelines, and Germany, France, and the United Kingdom anchor demand for sustained-release implants. Middle East and Africa show nascent but rising adoption as Gulf Cooperation Council health systems modernise; however, broader continental growth is hampered by limited specialist capacity. South America records moderate expansion led by Brazil’s sizeable population and improving reimbursement structures, though currency volatility and budget constraints temper premium biologic penetration.

List of Companies Covered in this Report:

• Abbvie
• Novartis
• Bausch + Lomb Corp.
• EyePoint Pharmaceuticals Inc.
• Alimera Sciences Inc.
• Santen Pharmaceutical Co. Ltd.
• Clearside Biomedical Inc.
• Eyegate Pharmaceuticals Inc.
• Roche
• Johnson & Johnson Vision Care
• UCB
• Regeneron Pharmaceuticals
• Aurinia Pharmaceuticals Inc.
• Sun Pharmaceuticals Industries
• ANI Pharmaceuticals Inc.
• ONL Therapeutics
• IVERIC Bio (Astellas)
• Oculis Holding AG
• Oxurion
• Acelyrin Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support